國藥科技股份(08156.HK)擬溢價約338%向陳霆發行5463.76萬股貸款資本化股份
格隆匯7月27日丨國藥科技股份(08156.HK)公吿,於2022年7月27日,公司與認購人陳霆先生訂立貸款資本化協議,據此公司有條件同意配發及發行,而認購人有條件同意按貸款資本化認購價認購5463.76萬股貸款資本化股份,其將透過抵銷貸款的全部金額來滿足。完成後,該貸款將被視為已全部償還,公司將解除其在該貸款項下的責任。
貸款資本化認購價為每股貸款資本化股份0.28港元,較本公吿日期在聯交所所報每股股份收市價0.064港元溢價約338%。
貸款資本化股份佔(i)截至本公吿日期的現有已發行股份數目約1.20%;及(ii)經貸款資本化股份擴大的已發行股份數目約1.19%。
董事認為,貸款資本化協議將允許公司在不動用集團現有財務資源的情況下清償公司欠認購人的未償款項,同時降低負債水平,從而加強集團的財務狀況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.